Indications
| Mesh Heading | Maximum Phase | Reference |
|---|---|---|
| Arthritis; Arthritis, Rheumatoid | Phase 3 | ClinicalTrials |
| Arthritis; Arthritis, Rheumatoid | Phase 2 | ClinicalTrials |
| Arthritis; Arthritis, Rheumatoid | Phase 2 | ClinicalTrials |
| Arthritis; Arthritis, Rheumatoid | Phase 2 | ClinicalTrials |
| Autoimmune Diseases; Connective Tissue Diseases; Lupus Erythematosus, Systemic | Phase 3 | ClinicalTrials |
| Autoimmune Diseases; Connective Tissue Diseases; Lupus Erythematosus, Systemic | Phase 3 | ClinicalTrials |
| Arthritis; Arthritis, Rheumatoid | Phase 3 | ClinicalTrials |
| Arthritis; Arthritis, Rheumatoid | Phase 2 | ClinicalTrials |
| Arthritis; Arthritis, Rheumatoid | Phase 1 | ClinicalTrials |
| Arthritis; Arthritis, Rheumatoid | Phase 3 | ClinicalTrials |
| Multiple Myeloma; Neoplasms, Plasma Cell | Phase 1 | ClinicalTrials |
| Kidney Diseases; Kidney Failure, Chronic; Renal Insufficiency | Phase 2 | ClinicalTrials |
| Arthritis; Arthritis, Rheumatoid | Phase 2 | ClinicalTrials |
| Autoimmune Diseases; Connective Tissue Diseases; Lupus Erythematosus, Systemic | Phase 3 | ClinicalTrials |
| Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Sclerosis | Phase 2 | ClinicalTrials |
| Arthritis; Arthritis, Rheumatoid | Phase 3 | ClinicalTrials |
CONTENTS